Gals Bio

Company Overview

Snapshot

Founded in October 2015 by Hilla Shaviv, Gals Bio operates with 1–10 employees. The company has raised $1.96M across two funding rounds from two investors. Gals Bio is actively developing solutions for women's health, including its Tulipon device for early cancer screening.

Business overview

Gals Bio is a Health Tech & Life Sciences company pioneering Fem-Wearables, a new category in women’s health and wellness. The company leverages the unique vaginal environment and AI-powered analysis to provide personalized, early, and accessible home health solutions. Its core product, Tulipon, is designed for clean collection of vaginal secretions for cancer screening, aiming to minimize human interference and prevent errors and contamination. Gals Bio serves the global market, focusing on women of any age with abnormal bleeding, BRCA mutations, or high cancer risk, operating within the Digital Health and Medical Technologies sectors.

Strategic signal

In January 2022, Gals Bio was highlighted in an article discussing its efforts to revolutionize the femtech market with its new smart tampon technology. This signals the company's ambition to innovate within women's health by introducing advanced, user-friendly diagnostic tools, positioning it as a key player in the evolving landscape of digital medical diagnostics and home-care solutions.

Company Intelligence Q&A

What is Gals Bio's primary focus?

Gals Bio is focused on pioneering Fem-Wearables, a new category in women’s health and wellness, by integrating AI-powered analysis with unique vaginal environment data to provide accessible home health solutions.

When was Gals Bio founded?

Gals Bio was founded in October 2015 by Hilla Shaviv.

What is the Tulipon device?

Tulipon is Gals Bio's first device, designed for the clean collection of vaginal secretions for cancer screening. It features a liquid-lock mechanism to preserve samples for AI-powered liquid biopsy analysis, aiming for early detection and convenience in reproductive health diagnostics.

What is Gals Bio's latest product development?

Gals Bio's latest product development is the Tulipon device, which was highlighted in January 2022 for its potential to revolutionize the femtech market with smart tampon technology for early cancer screening.

What market is Gals Bio targeting?

Gals Bio targets the global market, with a focus on women of any age who have abnormal bleeding, BRCA mutations, or a high risk of cancer, providing solutions for early-stage detection and monitoring.